^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclosporine

    Company:
    Generic mfg.
    Drug class:
    Calcineurin inhibitor
    Related drugs:
    21h
    COMPARE: Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study (clinicaltrials.gov)
    P4, N=50, Recruiting, Erasmus Medical Center
    New P4 trial
    |
    cyclosporine
    3d
    Observation on the efficacy of 0.05% cyclosporine in treating dry eye syndrome caused by thyroid-associated ophthalmopathy (ChiCTR2500115401)
    P=N/A, N=66, Recruiting, Northern Theater Command General Hospital of the Chinese People's Liberation Army; Northern Theater Command General Hospital of the Chinese People's L
    New trial
    |
    cyclosporine
    3d
    Comparison of the application effect of cyclosporine combined with sufentanil versus cyclosporine combined with remifentanil in painless gastroscopy in elderly patients (ChiCTR2500114516)
    P=N/A, N=174, Not yet recruiting, Hohhot First Hospital; Hohhot First Hospital
    New trial
    |
    cyclosporine • Sufenta (sufentanil)
    3d
    The Effects of Propofol and Cipropofol on Perioperative Neurocognitive Disorders in Elderly Patients (ChiCTR2600117749)
    P4, N=134, Not yet recruiting, Inner Mongolia Medical University Affiliated Hospital; Inner Mongolia Medical University Affiliated Hospital
    New P4 trial
    |
    cyclosporine
    3d
    Efficacy and Safety of Herombopag Ethanolamine Tablets in Combination with Cyclosporine and Androgen for the Treatment of Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) Patients—A Single-Arm, Prospective, Multicenter Phase II Clinical Study (ChiCTR2500114419)
    P4, N=42, Recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P4 trial
    |
    cyclosporine
    5d
    CsA/Met: Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone (clinicaltrials.gov)
    P1, N=32, Completed, Cairo University
    New P1 trial
    |
    metformin • cyclosporine
    7d
    Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (clinicaltrials.gov)
    P1/2, N=43, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Oct 2026 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • Zolinza (vorinostat) • cyclosporine
    14d
    Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov)
    P4, N=10, Not yet recruiting, University of California, San Francisco
    New P4 trial
    |
    5-fluorouracil • Jakafi (ruxolitinib) • hydroxychloroquine • cyclosporine • roflumilast • tofacitinib • Cosentyx (secukinumab) • Dupixent (dupilumab) • Ilumya (tildrakizumab-asmn) • chloroquine phosphate
    25d
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=80 --> 39
    Enrollment closed • Enrollment change
    |
    Promacta (eltrombopag) • cyclosporine
    28d
    A Case of Severe Skin Adverse Reactions Caused by Cetuximab. (PubMed, J Vis Exp)
    Management involved permanent discontinuation of cetuximab, high-dose intravenous methylprednisolone (1.5 mg∙kg-1∙day-1), cyclosporine (3 mg∙kg-1∙day-1), supportive wound care in a burn unit, and topical ocular/oral care...Therapy was successfully transitioned to bevacizumab plus FOLFOX after dermatologic recovery, with no rash recurrence during follow-up. This case highlights the importance of early recognition, multidisciplinary management, and protocol-driven intervention for severe cetuximab-induced skin toxicity to ensure patient safety and treatment continuity.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • CRP (C-reactive protein)
    |
    KRAS wild-type • RAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium • cyclosporine • methylprednisolone sodium succinate
    1m
    Drug-Induced Partial Immunosuppression for Preclinical Human Tumor Xenograft Models. (PubMed, Cancers (Basel))
    This drug-induced partial immunosuppression protocol effectively creates a reproducible state of transient immunodeficiency in outbred mice, suitable for various human tumor xenograft models. It represents a cost-effective and flexible alternative to genetic models, with the distinct advantage of preserving a residual immune microenvironment, making it particularly valuable for preclinical studies that require a partially intact host immune system.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • cyclosporine
    1m
    PM-003: TRACK-TBI Precision Medicine Part 3 - Option II (clinicaltrials.gov)
    P2, N=26, Enrolling by invitation, University of California, San Francisco | Not yet recruiting --> Enrolling by invitation | Trial completion date: Oct 2026 --> May 2027 | Initiation date: Aug 2025 --> Dec 2025 | Trial primary completion date: May 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    cyclosporine